A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma

J. Corren, S. Weinstein, L. Janka, C. O'Brien, J. Zangrilli (Los Angeles, Huntington Beach, Frazer, United States Of America)

Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Session: Clinical trials of drugs for respiratory diseases
Session type: Oral Presentation
Number: 4673
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Corren, S. Weinstein, L. Janka, C. O'Brien, J. Zangrilli (Los Angeles, Huntington Beach, Frazer, United States Of America). A randomized phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. Eur Respir J 2014; 44: Suppl. 58, 4673

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
A randomized phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014

Pharmacological effect of lysozyme for COPD and bronchial asthma with sputum: A randomized, placebo-controlled, cross-over study
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014


Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma
Source: Annual Congress 2013 –Studies of asthma in man
Year: 2013

Experience with omalizumab in patients with moderate and severe asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Efficacy and safety of isoproterenol continuous inhalation treatment for acute severe exacerbation of asthma in children; a randomized, double-blind controlled study
Source: International Congress 2015 – Paediatric asthma and allergy: asthma management
Year: 2015


QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014


APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma
Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Year: 2015


Aerobic training decrease bronchial hyperresponsiveness and systemic inflammation in patients with moderate or severe asthma: A randomized controlled trial
Source: International Congress 2014 – Best abstracts in pulmonary rehabilitation and exercise training
Year: 2014


Benralizumab effect on blood basophil counts in adults with uncontrolled asthma
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


Omalizumab in allergic eosinophilic asthma and lung eosinophil numbers: A 78-week randomized controlled trial
Source: Annual Congress 2013 –Treatment of asthma
Year: 2013


Aerobic training decreases bronchial hyperresponsiveness, serum chemokines and symptoms in asthmatic patients: Randomized controlled trial
Source: Annual Congress 2013 –Rehabilitation, exercise and adjunct physiotherapy techniques in different respiratory conditions
Year: 2013


Abediterol in stable asthma:efficacy, safety and tolerability results from a Phase II, randomised, crossover study
Source: International Congress 2014 – Asthma and COPD management
Year: 2014

Reslizumab (RES) in patients (pts) with inadequately controlled asthma and elevated blood eosinophils (EOS): Analysis of two phase 3, placebo-controlled trials
Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives
Year: 2016



Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014


Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Predictors of effectiveness of omalizumab treatment in patients with severe asthma recruited in a real-life setting
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015


Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014


LATE-BREAKING ABSTRACT: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: the SIRIUS study
Source: International Congress 2014 – The future has started: emerging potentials for personalised asthma treatment
Year: 2014

P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients
Source: International Congress 2016 – Asthma management
Year: 2016

Blood eosinophil dose response to oral corticosteroids in a population of patients with severe asthma
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016